Our data demonstrated that the frequency of co-alterations between EGFR and other driver genes (ALK, ROS1, RET, PIK3CA, BRAF, KRAS, NRAS, BRAF) in NSCLC was 6.6%. This evidence concerns the gene KRAS and non-small cell lung carcinoma.